Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use REVCOVI® safely and effectively. See full prescribing information for REVCOVI. REVCOVI (elapegademase-lvlr) injection, for intramuscular use Initial U.S. Approval: 2018
Medication labelWhy this: Advisory · dailymed-prescription
REVCOVI is indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.
- generic_name
- elapegademase-lvlr
- product_names
- elapegademase-lvlr
- ndc
- 10122-502, 10122-502-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en